4.5 Article

Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient

Journal

NEUROLOGICAL SCIENCES
Volume 42, Issue 12, Pages 5377-5378

Publisher

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-021-05557-9

Keywords

Myasthenia; Lambert-Eaton; Immune-related adverse event; Neurology; Checkpoint inhibitors; Melanoma

Ask authors/readers for more resources

This study presents a rare case of MG-LE overlap syndrome diagnosed after anti-PD1 immunotherapy for metastatic melanoma, which initially appeared after radiation therapy and relapsed after brain radiation necrosis. The potential role of brain inflammation as a trigger for MG-LE onset is hypothesized. Neuro-muscular junctions disease induced or revealed by checkpoint inhibitors can be challenging and necessitate long-term follow-up.
Introduction Myasthenia gravis (MG) Lambert-Eaton (LE) overlap syndrome is a rare condition. Here, we describe the first case of MG-LE overlap syndrome revealed by the anti-programmed cell death 1 inhibitor, nivolumab, in a patient treated for metastatic melanoma. Case Three months after receiving nivolumab and 1 month after brain metastasis radiotherapy, our patient developed generalized fatigue with intermittent ptosis and swallowing difficulty suggesting a myasthenic syndrome. Electromyogram findings, anti-acetylcholine receptor, and anti-calcium channel antibodies levels were consistent with an immune-related myasthenic syndrome with specific features for both MG and LE syndromes. Immunotherapy with nivolumab was stopped. Patient was treated with systemic immunosuppressive and anti-cholinesterase drugs, with remarkable improvement of his neurological symptoms. Prolonged partial remission was obtained for his metastatic melanoma without need for a third-line treatment. Two years later, a relapse of hismyasthenic symptoms was observed along with new neurological symptoms related to brain radiation necrosis. Conclusion We describe the first case of MG-LE overlap syndrome diagnosed after anti-PD1 immunotherapy for metastatic melanoma, which appeared after radiation therapy and then relapsed after brain radiation necrosis. We hypothesized a role for brain inflammation as a trigger for MG-LE onset. Neuro-muscular junctions disease induced or revealed by checkpoint inhibitors can be challenging and requires long-term follow-up.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available